— Endo International plc (NASDAQ: ENDP) reported Q3 2019 earnings of $0.60 per share, vs. $0.53 expected.
— Revenues fell 2% to $729 million, vs. $709 million expected.
— Specialty Products revenues increased 18% to $132 million.
— Sterile Injectables revenues grew 11% to $264 million.
— FY19 revenues are expected to be between $2.86 billion and $2.89 billion.
— FY19 adjusted EPS from continuing operations is expected to be $2.10 and $2.25.
— ENDP shares were down 3% in premarket hours on Tuesday.
Get access to timely and accurate verbatim transcripts that are published within hours of the event.
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on
